How to Switch from Victoza 1.8 mg Daily to Tirzepatide
You can switch directly from liraglutide (Victoza) 1.8 mg daily to tirzepatide 2.5 mg weekly without a washout period, starting tirzepatide the day after the last liraglutide dose.
Direct Switching Protocol
The transition from liraglutide to tirzepatide is straightforward:
- Stop liraglutide and start tirzepatide 2.5 mg weekly the next day 1
- No washout period is required between medications
- Begin with the standard starting dose of tirzepatide 2.5 mg weekly regardless of prior liraglutide dose 1
Tirzepatide Titration Schedule
After initiating tirzepatide at 2.5 mg weekly, follow this monthly escalation:
- Week 0-4: Tirzepatide 2.5 mg weekly (starting dose)
- Week 4-8: Increase to 5 mg weekly
- Week 8-12: Increase to 7.5 mg weekly (if additional control needed)
- Week 12-16: Increase to 10 mg weekly (if additional control needed)
- Week 16+: Increase to maximum 15 mg weekly (if additional control needed)
The 2.5 mg dose is specifically designed to reduce gastrointestinal symptoms during initial titration 1. Monthly dose escalation allows the body to acclimate and minimizes adverse effects.
Expected Clinical Outcomes
Real-world evidence demonstrates that switching from GLP-1 RAs like liraglutide to tirzepatide produces meaningful improvements:
- A1C reduction: Additional 0.4-1.4% decrease over 3-6 months 2, 3
- Weight loss: Additional 2-6 kg reduction over 3-6 months 2, 3
- Most improvements occur by 12 weeks, with continued benefit through 6 months 2, 3
Patients already on liraglutide 1.8 mg (maximum dose) who switch to tirzepatide 5 mg show mean A1C reduction of -0.43% and weight loss of -2.15 kg at 12 weeks 2. Greater reductions occur with higher tirzepatide doses.
Insulin Dose Adjustments (If Applicable)
If your patient is also on insulin, proactively reduce insulin doses to prevent hypoglycemia:
- Expect a median 9-10% reduction in total daily insulin requirements over 6 months 4
- Patients with baseline A1C ≤8.0% require larger insulin reductions (median -22.6%) compared to those with A1C >8.0% 4
- Consider reducing basal insulin by 10-20% at the time of switch, with further adjustments based on glucose monitoring
- Monitor glucose closely during the first 4-8 weeks when tirzepatide effects are increasing
Managing Gastrointestinal Side Effects
The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea), occurring primarily during dose escalation 1:
Prevention strategies:
- Slow titration is essential - do not accelerate the monthly dose increases 1
- Counsel patients to avoid fatty foods, eat smaller portions, and stop eating before feeling full 1
- Reassure patients that GI symptoms are typically transient and diminish over time 5
In the prospective switching study, only 13.2% developed GI events and only 2% discontinued due to adverse effects 2. This suggests patients already tolerating liraglutide generally tolerate tirzepatide well.
Common Pitfalls to Avoid
Do not start at higher tirzepatide doses - even though the patient tolerated liraglutide 1.8 mg, always start tirzepatide at 2.5 mg weekly 1
Do not skip the 2.5 mg starting dose - this dose specifically reduces GI symptoms during initiation 1
Do not forget insulin adjustments - tirzepatide has more potent glucose-lowering effects than liraglutide, increasing hypoglycemia risk if insulin is not reduced 4
If the patient misses >3 days of tirzepatide, restart at 2.5 mg weekly to mitigate GI symptoms, similar to liraglutide reinitiation protocols 6
Contraindications and Precautions
Both medications share similar contraindications:
- Personal or family history of medullary thyroid carcinoma 5
- Multiple endocrine neoplasia syndrome type 2 5
- History of pancreatitis - consider alternative therapies 5
Monitor for rare but serious adverse effects including pancreatitis, gallbladder disease (increased with weight loss), and mood changes 1.
Renal Dosing
No dose adjustment is required for tirzepatide in chronic kidney disease, similar to liraglutide 7, 8. Both medications can be used safely across the spectrum of kidney function, making the switch straightforward even in patients with CKD.